Company intelligence / Profile preview

Burlex

Wayne, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Berlex was a major pharmaceutical company that operated as the U.S. subsidiary of the German firm Schering AG. The company was best known for its leadership in specialized therapeutic areas, particularly women's healthcare, diagnostic imaging, and oncology. Its most significant product was Betaseron (interferon beta-1b), which was the first disease-modifying therapy approved for the treatment of relapsing-remitting multiple sclerosis. Following the acquisition of Schering AG by Bayer in 2006, Berlex was integrated into Bayer's pharmaceutical operations, eventually becoming part of Bayer HealthCare Pharmaceuticals.

Therapeutic areas: OtherOncologyNeurologyWomen's Health
Modalities: Small moleculeMonoclonal antibodyRecombinant proteinHormone
Industry: Pharma

Partnerships

Chiron CorporationImmunex

Beyond the preview

Go deeper on Burlex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Burlex.

Explore the full profile